甘李药业胰岛素周制剂GZR4注射液中国2型糖尿病III期临床研究SUPER-2完成首例受试者给药

Core Viewpoint - Ganli Pharmaceutical Co., Ltd. has announced the initiation of a large-scale Phase III clinical study (SUPER-2) for its self-developed basal insulin GZR4 injection in China, marking the first global Phase III clinical study for this product [1] Group 1 - The Phase III clinical study targets type 2 diabetes mellitus (T2DM) patients who have previously received basal insulin treatment [1] - The first subject has been dosed in this significant clinical trial, indicating progress in the development of GZR4 injection [1] - This study represents a key milestone for Ganli Pharmaceutical in its research and development efforts for diabetes treatment [1]